LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC)

被引：3
|
作者：
Hirschfield, G. [1 ]
Kowdley, K. [2 ]
Mason, A. [3 ]
Luketic, V. [4 ]
Gordon, S. [5 ]
Vincent, C. [6 ]
Mayo, M. [7 ]
Pares, A. [8 ]
Chapman, R. [9 ]
Lindor, K. [10 ]
Esguerra, M.
Eliot, L. [11 ]
Shapiro, D.
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[3] Univ Alberta, Edmonton, AB, Canada
[4] Virginia Commonwealth Univ, Richmond, VA USA
[5] Henry Ford Hlth Ctr, Detroit, MI USA
[6] Hop St Luc, CHUM, Montreal, PQ H2X 1P1, Canada
[7] UT SW Med Ctr, Dallas, TX USA
[8] Hosp Clin Barcelona, Barcelona, Spain
[9] John Radcliffe Hosp, Headington, England
[10] Mayo Clin, Rochester, MN USA
[11] LKAN Clin, San Diego, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)60964-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
952
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [1] A LONG TERM SAFETY EXTENSION TRIAL OF THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) AND UDCA IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Hirschfield, Gideon M.
    Mason, Andrew L.
    Gordon, Stuart C.
    Luketic, Velimir A.
    Mayo, Marlyn
    Vincent, Catherine
    Lindor, Keith D.
    Pares, Albert
    Kowdley, Kris V.
    Trauner, Michael
    Esguerra, Maria
    Boehm, Olaf
    Shapiro, David A.
    HEPATOLOGY, 2011, 54 : 429A - 429A
  • [2] THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Marschall, H. -U.
    Luketic, V.
    Lovgren-Sandblom, A.
    Benthin, L.
    Kowdley, K.
    Hirschfield, G.
    Mason, A.
    Lindor, K.
    Gordon, S.
    Vincent, C.
    Chapman, R.
    Mayo, M.
    Burroughs, A.
    Pares, A.
    Jones, D.
    Schramm, C.
    Eliot, L.
    Hofmann, A. F.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S377 - S377
  • [3] LONG-TERM TREATMENT OF PRIMARY BILIARY CIRRHOSIS WITH THE FXR AGONIST OBETICHOLIC ACID SHOWS DURABLE EFFICACY
    Kowdley, K.
    Hirschfield, G.
    Chapman, R.
    Vincent, C.
    Jones, D.
    Pares, A.
    Luketic, V.
    Gordon, S.
    Pencek, R.
    Marmon, T.
    Hooshmand-Rad, R.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S192 - S193
  • [4] Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)
    Bowlus, C.
    Pockros, P.
    Kremer, A. E.
    Pares, A.
    Forman, L.
    Drenth, J. P.
    Ryder, S.
    Malecha, E. S.
    Pencek, R.
    Iloeje, U.
    Macconell, L.
    Shapiro, D.
    Pierre, B.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S111 - S112
  • [5] THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES - AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS
    Nevens, F.
    Andreone, P.
    Mazzella, G.
    Strasser, S.
    Bowlus, C.
    Invernizzi, P.
    Drenth, J.
    Pockros, P.
    Regula, J.
    Hansen, B.
    Hooshmand-Rad, R.
    Sheeron, S.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S525 - S526
  • [6] The First New Trials for Primary Biliary Cirrhosis in a Decade: An International Program Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid
    Kowdley, Kris y
    Nevens, Frederik
    Andreone, Pietro
    Luketic, Velimir A.
    Shah, Hemant
    Pencek, Richard
    Marmon, Tonya K.
    Shapiro, David
    GASTROENTEROLOGY, 2015, 148 (04) : S991 - S992
  • [7] The cancerogenic potential of primary human Cholangioracinoma cells is inhibited by Obeticholic Acid, a Farnesoid X Receptor (FXR) agonist
    Di Matteo, S.
    Nevi, L.
    Costantini, D.
    Colantonio, M.
    Giulitti, F.
    Napoletano, C.
    Safarikia, S.
    Manzi, E.
    Derose, A. M.
    Melandro, F.
    Bragazzi, M. C.
    Grazi, G.
    Berloco, P. B.
    Giuliante, F.
    Carpino, G.
    Cardinale, V.
    Gaudio, E.
    Alvaro, D.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (01) : 22 - 23
  • [8] LONG-TERM SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
    Peters, Y.
    Hooshmand-rad, R.
    Pencek, R.
    Owens-grillo, J.
    Marmon, T.
    Macconell, L.
    Picaro, L. A.
    Adorini, L.
    Shapiro, D.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E117 - E118
  • [9] FXR Agonist Obeticholic Acid: Sustained Improvement in Markers of Cholestasis and Long-Term Safety in Patients with Primary Biliary Cirrhosis through 4 Years
    Kowdley, Kris V.
    Pencek, Richard
    Marmon, Tonya
    Shapiro, David
    Hooshmand-Rad, Roya
    HEPATOLOGY, 2014, 60 : 361A - 361A
  • [10] Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
    Corpechot, Christophe
    Abenavoli, Ludovico
    Rabahi, Nabila
    Chretien, Yves
    Andreani, Tony
    Johanet, Catherine
    Chazouilleres, Olivier
    Poupon, Raoul
    HEPATOLOGY, 2008, 48 (03) : 871 - 877
12345